Board of Directors

J. Stark Thompson, Ph.D. has been non-executive Chairman of the Board of the Company since November 2004 and has served as a director since February 2002. From 1988 until his retirement in November 2000, Dr. Thompson served as the President, Chief Executive Officer and as a director of Life Technologies, Inc., a developer, manufacturer and supplier of products and services for life science research. Dr. Thompson is a Director of Luminex Corporation, where he serves on the Auditing and Nominating Committees. Dr. Thompson has a Ph.D. in Physiological Chemistry from Ohio State University.

Michael J. Brennan, M.D., Ph.D. has served as a director since December 1995. Since his retirement as the Company’s Chief Executive Officer in 2000 and the Chairman of the Board in 2001, Dr. Brennan has been employed by the Company as Director of Strategic Initiatives. Since January 2006, Dr. Brennan has been Managing Director of Pearl Street Venture Funds, a venture capital firm. From December 2003 until December 2005, Dr. Brennan was a Managing Director of Coastview Capital, a venture capital firm focused exclusively on life science investments. From September 2000 until April 2003, Dr. Brennan was a General Partner of Oxford Biosciences Partners, a venture capital firm specializing in the financing of early stage healthcare companies. Dr. Brennan received a Ph.D. in neurobiology and an M.D. from the University of Witwatersrand, Johannesburg, South Africa.

From March 2007, Charles Dimmler has been President & Chief Executive Officer of Ore Pharmaceuticals Inc. [formerly Gene Logic Inc.]. Since 1982, he has been an entrepreneur, venture capitalist, private investor and business executive specializing in businesses related to healthcare. His professional fields of interest have included genomics, stem cells, biopharmaceuticals and disease management companies.

During the period April 2004 – May 2006, Mr. Dimmler served as Executive Chairman of the Board of Directors, then Chief Executive Officer, of Nobex Corporation. Retained by the Board to rationalize the company, he executed the sale of the company’s assets to Biocon Limited [Bangalore, India].

Mr. Dimmler is formerly Chief Executive Officer and Chairman of the Board of Directors of Lundbeck, Inc., a wholly owned subsidiary of H. Lundbeck A/S where he also served as Chief Investment Officer of H. Lundbeck A/S. Lundbeck is a fully integrated global pharmaceutical company specializing in proprietary ethical drugs to treat diseases of the central nervous system.

For more than a decade, Mr. Dimmler was a general partner of two New York based private equity units of the London merchant bank Hambros plc.: Hambro International Equity Partners and the Cross Atlantic Partners Funds. Consisting of capital provided solely by financial institutions and strategic partners in Scandinavia, Cross Atlantic Partners invested its funds exclusively in emerging life science companies in the US.

In May 1982, Mr. Dimmler co-founded the biotechnology company Applied Immune Sciences, Inc. At the outset of his business career, Mr. Dimmler served as an operating executive of two Fortune 100 companies where he held a succession of assignments in sales and marketing, business development, and general management positions in technology intensive businesses serving the pharmaceutical, medical device, semiconductor, chemical process and petroleum refining industries.

After earning his undergraduate degree at the University of California at Davis, Mr. Dimmler served as an infantry officer in the United States Marine Corps. He has completed graduate course work in several professional programs, including the Advanced Management Program of the Harvard Business School.

Mark J. Gabrielson was appointed a director in April 2007. Mr. Gabrielson is founder and Managing General Partner of p-Value Capital LLC, an investment management firm focused on special situations in the pharmaceutical industry. Mr. Gabrielson also is a co-founder and Director of Pulmatrix Inc., a privately held company that is developing inhalant technologies to help control respiratory infectious disease. From March 2003 until January 2008, Mr. Gabrielson served as the Chief Executive Officer of Pulmatrix Inc. From 1998 until December 2003, Mr. Gabrielson was a founder and Managing Member of Fordyce & Gabrielson LLC, a venture capital firm where he led a series of investments in early stage technology-intensive companies, including Pulmatrix. From 1990 to1999, Mr. Gabrielson was a General Partner of Prince Ventures LP, a private venture capital firm specializing in healthcare investing. Mr. Gabrielson holds an A.B. Degree from Princeton University.

Mark D. Gessler has served as a director since 2000. From June 2000 until March 2007, Mr. Gessler served as Chief Executive Officer of the Company, and from January 1999 until March 2007, as President of the Company. From April 2001 to November 2004, Mr. Gessler served as the Company’s Chairman of the Board of Directors. Mr. Gessler holds an MBA from the University of Tennessee.

G. Anthony Gorry, Ph.D. has served as a director since January 1997. Since prior to March 2001, Dr. Gorry has been the Friedkin Professor of Management and Professor of Computer Science at Rice University, where he also serves as the Director of the Center for Technology in Teaching and Learning. Dr. Gorry directs a training grant on computational biology funded by the National Library of Medicine. He is also Adjunct Professor of Neuroscience at Baylor College of Medicine. Dr. Gorry holds a B.Eng. from Yale University, an M.S. in chemical engineering from the University of California, Berkeley and a Ph.D. in computer science from the Massachusetts Institute of Technology.

David L. Urdal, Ph.D. was appointed a director in April 2007. Dr. Urdal is a Senior Vice President of Dendreon Corporation and has been the Chief Scientific Officer and a Director since July 1995. Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. Previously, he served as Dendreon’s President from January 2001 to December 2003 and as its Executive Vice President from January 1999 through December 2000. From 1982 until July 1995, Dr. Urdal held various positions with Immunex Corporation, including President of Immunex Manufacturing Corporation, Vice President and Director of Development, and Head of the departments of biochemistry and membrane biochemistry. Dr. Urdal received a Ph.D. in Biochemical Oncology from the University of Washington.